HIF-1&#945; is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia by Griggio, Valentina et al.
HIF-1a is overexpressed in leukemic cells from 
TP53-disrupted patients and is a promising therapeutic
target in chronic lymphocytic leukemia
by Valentina Griggio, Candida Vitale, Maria Todaro, Chiara Riganti, Joanna Kopecka, 
Chiara Salvetti, Riccardo Bomben, Michele Dal Bo, Daniela Magliulo, Davide Rossi, 
Gabriele Pozzato, Lisa Bonello, Monia Marchetti, Paola Omedè, Ahad Ahmed Kodipad, 
Luca Laurenti, Giovanni Del Poeta, Francesca Romana Mauro, Rosa Bernardi, Thorsten Zenz,
Valter Gattei, Gianluca Gaidano, Robin Foà, Massimo Massaia, Mario Boccadoro, 
and Marta Coscia 
Haematologica 2019 [Epub ahead of print]
Citation: Valentina Griggio, Candida Vitale, Maria Todaro, Chiara Riganti, Joanna Kopecka, 
Chiara Salvetti, Riccardo Bomben, Michele Dal Bo, Daniela Magliulo, Davide Rossi,
Gabriele Pozzato, Lisa Bonello, Monia Marchetti, Paola Omedè, Ahad Ahmed Kodipad,
Luca Laurenti, Giovanni Del Poeta, Francesca Romana Mauro, Rosa Bernardi, Thorsten Zenz, 
Valter Gattei, Gianluca Gaidano, Robin Foà, Massimo Massaia, Mario Boccadoro, and Marta Coscia. 
HIF-1a is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic
target in chronic lymphocytic leukemia. 
Haematologica. 2019; 104:xxx
doi:10.3324/haematol.2019.217430
Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science.
Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that
have completed a regular peer review and have been accepted for publication. E-publishing
of this PDF file has been approved by the authors. After having E-published Ahead of Print,
manuscripts will then undergo technical and English editing, typesetting, proof correction and
be presented for the authors' final approval; the final version of the manuscript will then
appear in print on a regular issue of the journal. All legal disclaimers that apply to the
journal also pertain to this production process.
 Copyright 2019 Ferrata Storti Foundation.
Published Ahead of Print on July 9, 2019, as doi:10.3324/haematol.2019.217430.
GRIGGIO V et al  HIF-1α IN TP53 DISRUPTED CLL CELLS 
1 
 
Title Page 
Article title: HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and 
is a promising therapeutic target in chronic lymphocytic leukemia 
Running head: HIF-1α in TP53-disrupted CLL Cells 
Authors: Valentina Griggio1,2, Candida Vitale1,2, Maria Todaro1,2, Chiara Riganti3, Joanna 
Kopecka3, Chiara Salvetti1,2, Riccardo Bomben4, Michele Dal Bo4, Daniela Magliulo5, 
Davide Rossi6, Gabriele Pozzato7, Lisa Bonello2, Monia Marchetti8, Paola Omedè1, Ahad 
Ahmed Kodipad9, Luca Laurenti10, Giovanni Del Poeta11, Francesca Romana Mauro12; 
Rosa Bernardi5, Thorsten Zenz13, Valter Gattei4, Gianluca Gaidano9, Robin Foà12, 
Massimo Massaia14, Mario Boccadoro1,2 and Marta Coscia1,2 
Affiliations:  
1Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy; 
2Department of Molecular Biotechnology and Health Sciences, University of Torino, 
Torino, Italy 
3Department of Oncology, University of Torino, Turin, Italy 
 4Clinical and Experimental Onco-Hematology Unit, CRO Aviano National Cancer Institute, 
Aviano, Italy 
5Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; 
6Department of Hematology, Oncology Institute of Southern Switzerland and Institute of 
Oncology Research, Bellinzona, Switzerland 
7Department of Internal Medicine and Hematology, Maggiore General Hospital, University 
of Trieste, Trieste, Italy 
8Hematology Day Service, Oncology SOC, Hospital Cardinal Massaia, Asti, Italy  
9Division of Hematology, Department of Translational Medicine, University of Eastern 
Piedmont, Novara, Italy 
GRIGGIO V et al  HIF-1α IN TP53 DISRUPTED CLL CELLS 
2 
 
10Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy  
11Division of Hematology, S. Eugenio Hospital and University of Tor Vergata, Rome, Italy 
12Hematology, Department of Translational and Precision Medicine, Sapienza University, 
Policlinico Umberto I, Rome, Italy 
13Department of Medical Oncology and Hematology, University Hospital and University of 
Zurich, Zurich, Switzerland 
14Hematology Unit, ASO Santa Croce e Carle, Cuneo, Italy  
 
Corresponding Author: Dr. Marta Coscia, Division of Hematology, Department of 
Molecular Biotechnology and Health Sciences, University of Torino, Azienda Ospedaliero-
Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, 
Italy. Phone Number: +390116336728; Fax Number: +390116963737; e-mail address: 
marta.coscia@unito.it 
V.Griggio and C.V. contributed equally to this study. 
Word count: 3801 
Tables and Figures: 7 
Supplemental files: 1 
Acknowledgements 
The authors would like to thank: Italian Association for Cancer Research (AIRC IG15232 
and IG21408) (C.R.), (AIRC IG13119, AIRC IG16985, AIRC IG2174) (M.Massaia), (AIRC 
IG17622) (V.Gattei), (AIRC 5x1000 project 21198, Metastatic disease: the key unmet need 
in oncology) (G.G) (AIRC 5x1000 Special Programs MCO-10007 and 21198) (R.F.); 
Fondazione Neoplasie Sangue (Fo.Ne.Sa), Torino, Italy; University of Torino (local funds 
ex-60%) (M.C.); Ministero della Salute, Rome, Italy (Progetto Giovani Ricercatori GR-
GRIGGIO V et al  HIF-1α IN TP53 DISRUPTED CLL CELLS 
3 
 
2011-02347441 [R.Bomben], GR-2009-1475467 [R.Bomben], and GR-2011-02351370 
[M.DB.]). Fondazione Cassa di Risparmio di Torino (CRT) (V.Griggio was recipient of a 
fellowship), Fondazione “Angela Bossolasco” Torino, Italy (V.Griggio was recipient of the 
“Giorgio Bissolotti e Teresina Bosio” fellowship), the Italian Association for Cancer 
Research (AIRC, Ref 16343 V.Griggio was recipient of the “Anna Nappa” fellowship and 
M.T. is currently the recipient of a fellowship from AIRC Ref 19653). Associazione Italiana 
contro le Leucemie, Linfomi e Mieloma (AIL) (C.V. was recipient of a fellowship). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GRIGGIO V et al  HIF-1α IN TP53 DISRUPTED CLL CELLS 
4 
 
 
Abstract  
In chronic lymphocytic leukemia, the hypoxia-inducible factor 1 (HIF-1) regulates the 
response of tumour cells to hypoxia and their protective interactions with the leukemic 
microenvironment. In this study we demonstrate that chronic lymphocytic leukemia cells 
from TP53-disrupted (TP53dis) patients have constitutively higher expression levels of the 
α-subunit of HIF-1 (HIF-1α) and increased HIF-1 transcriptional activity, compared to the 
wild type counterpart. In the TP53dis subset, HIF-1α upregulation is due to reduced 
expression of the HIF-1α ubiquitin ligase von Hippel-Lindau protein (pVHL). Hypoxia and 
stromal cells further enhance HIF-1α accumulation, independently from the TP53 status. 
Hypoxia acts through the downmodulation of pVHL and the activation of the PI3K/AKT and 
RAS/ERK1-2 pathways, whereas stromal cells induce an increased activity of the 
RAS/ERK1-2, RHOA/RHOA kinase and PI3K/AKT pathways, without affecting pVHL 
expression. Interestingly, we observed that higher levels of HIF-1A mRNA correlate with a 
lower susceptibility of leukemic cells to spontaneous apoptosis, and associate with the 
fludarabine resistance that mainly characterizes TP53dis tumour cells. The HIF-1α inhibitor 
BAY87-2243 exerts cytotoxic effects toward leukemic cells, regardless of the TP53 status, 
and has anti-tumour activity in Eµ-TCL1 mice. BAY87-2243 also overcomes the 
constitutive fludarabine resistance of TP53dis leukemic cells and elicits a strongly 
synergistic cytotoxic effect in combination with ibrutinib, thus providing preclinical 
evidences for its further investigation as a potential new drug in chronic lymphocytic 
leukemia. 
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Article summary 
1) The aim of this study is two-fold: i) to unravel HIF-1α regulatory pathways in chronic 
lymphocytic leukemia cells (CLL) from TP53-disrupted and wild type patients; ii) to 
provide preclinical evidences for the anti-tumour activity of the HIF-1α inhibitor 
BAY87-2243 in CLL. 
2) HIF-1α is overexpressed in leukemic cells from TP53-disrupted CLL patients, and is 
further upregulated by hypoxia and stromal cells. The HIF-1α inhibitor BAY87-2243 
exerts cytotoxic effects toward leukemic cells, sensitizes TP53-disrupted CLL cells 
to fludarabine and synergizes with ibrutinib.  
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Introduction 
Chronic lymphocytic leukemia (CLL) patients with high-risk genomic features such as 
disruption of the TP53 gene (i.e. del(17p) and TP53 mutations) respond poorly to 
chemoimmunotherapy and frequently relapse1–9. Significant advances have been made in 
the treatment of CLL following  the introduction of Bruton tyrosine kinase (BTK) inhibitors10. 
Ibrutinib, which is currently approved for the front-line treatment of CLL, induces long-
lasting responses in the majority of patients, improving outcome with relatively limited 
toxicities10. However, patients with disruption of the TP53 gene (TP53dis) treated with 
ibrutinib are still characterized by a poorer outcome11. 
Hypoxia inducible factor 1 (HIF-1) is an essential regulator of cell adaptation to hypoxia 
and is often upregulated in tumours due to intratumoural hypoxia or activation of 
oncogenic pathways12,13. In tumours, HIF-1 fosters different tumour-promoting 
mechanisms, including metabolic adaptation, neoangiogenesis, cell survival and 
invasion14.  
HIF-1 is a heterodimer, which consists of a constitutively expressed HIF-1β subunit and an 
inducible HIF-1α subunit. Besides its traditional regulation via proteasomal degradation, 
other signalling pathways, such as PI3K/AKT and RAS/ERK1-2, contribute to HIF-1α 
accumulation, via stability regulation or synthesis induction12,15.  
HIF-1α is constitutively expressed in CLL cells compared to normal B cells due to 
microRNA-mediated downregulation of the von Hippel-Lindau protein (pVHL)16, a ubiquitin 
ligase responsible for HIF-1α degradation12. In addition, in CLL cells HIF-1α is upregulated 
by the interactions with stromal cells (SC) and by exposure to hypoxic microenvironments, 
thus promoting the survival and propagation of leukemic cells, and their metabolic 
adaptation to the protective conditions of the tumour niche17–20. We have already reported 
that HIF-1α is involved in drug resistance mechanisms in patients with unmutated (UM) 
immunoglobulin heavy chain variable region genes (IGHV)20. TP53 gene encodes one of 
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the most well-studied tumour suppressor protein, which is often mutated in cancer, thus 
promoting cell survival, proliferation and drug resistance21. p53 may also play a pivotal role 
in the regulation of HIF-1α, since in conditions of prolonged hypoxia/anoxia the protein 
accumulates and promotes HIF-1α destruction22. In solid tumours, loss of TP53 function 
associates with constitutive elevated levels of HIF-1α12,22,23.  
In this study, we found that HIF-1α is overexpressed in CLL cells from patients carrying 
TP53 aberrations, also elucidating the molecular mechanisms implicated in the constitutive 
(TP53-related) and inducible (hypoxia- and SC-induced) HIF-1α upregulation. In addition, 
we documented that the HIF-1α inhibitor BAY87-2243 exerts potent anti-tumour functions, 
overcoming the constitutive fludarabine resistance of TP53-disrupted CLL cells and 
eliciting a strong synergistic cytotoxic effect in combination with ibrutinib. 
Methods 
Patients’ samples 
A total of 102 patients with CLL, diagnosed according to the International Workshop on 
CLL-National Cancer Institute guidelines24, were included in the study (40 TP53dis and 62 
TP53-wild type [TP53wt] cases) (Table 1 in Supplemental Information). Healthy donors’ 
(HD, n=2) samples were provided by the local blood bank. Patients were untreated or off-
therapy for at least 12 months before sampling of peripheral blood (PB) for the 
experiments. Samples were collected after patients’ informed consent, in accordance with 
the Declaration of Helsinki and approval by the local Institutional Review Board. PB 
mononuclear cells (PBMC) were isolated and characterized as detailed in Supplemental 
Information.  
Cell lines 
The Burkitt’s lymphoma cell line, Séraphine, and the mantle cell lymphoma cell line, 
Granta-519, were kindly provided by T. Zenz. In the study the TP53wt and the 
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CRISPR/Cas9-mediated TP53 knockout version (TP53ko) of Granta-519 and Séraphine 
cell lines were used. The M2-10B4 murine SC line (ATCC #CRL-1972) was also used. Cell 
lines were maintained as reported in Supplemental Information. 
Animals 
C57BL/6 Eμ-TCL1 mice were maintained in specific pathogen-free animal facilities and 
treated in accordance with European Union guidelines and Institutional Animal Care and 
Use Committee (number 716). Splenic cells (5x106) were injected intraperitoneally into 
syngeneic C57BL/6 mice, and experiments were performed with 4-6 mice groups. 
Leukemic mice were treated when tumour cells reached 10% in PB. BAY87-2243 was 
administered 4 mg/kg in ethanol/solutol/water solution once daily by oral gavage. Mice 
were sacrificed at the end of treatment. 
Cell culture  
In selected experiments, CLL cells were cultured in the presence or absence of M2-10B4 
SC, and exposed to PD98059 (Sigma Aldrich, Milan), Y27632 (Sigma Aldrich) or 
LY249002 (Sellekchem, Houston, TX) for 48 hours. CLL cells were exposed for 48 hours 
to BAY87-2243 (Sellekchem); 2-Fluoroadenine-9-β-D-arabinofuranoside (F-ara-A, Sigma 
Aldrich); ibrutinib (Sellekchem) used alone or in combination, at the indicated 
concentrations. Culture conditions were normoxia or mild hypoxia (1% O2), 5% CO2 at 
37°C.  
Western blot (WB) 
Full details can be found in Supplemental Information together with the list of antibodies 
used for WB analyses. 
Quantitative real-time PCR  
Full details can be found in Supplemental Information together with the list of primers 
sequences. 
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Gene set enrichment analysis  
“Gene Set Enrichment Analysis” (GSEA, http://www.broad.mit.edu/gsea/index.jsp) was 
performed as previously described25,26. Gene sets were assessed as significantly enriched 
in one of the phenotypes if the nominal p value and the FDR-q value were less than 0.05. 
RHOA and RAS, ERK1-2, AKT and RHOA kinase activity 
The isoprenylated membrane-associated RAS or RHOA proteins and the non-
isoprenylated cytosolic forms were detected as previously described20. ERK1-2, AKT and 
RHOA kinases activity measurement details are reported in Supplemental Information. 
Cell viability assay 
Cell viability was evaluated by flow cytometry using with Annexin-V/Propidium Iodide (Ann-
V/PI) staining with the MEBCYTO-Apoptosis Kit (MBL Medical and Biological Laboratories, 
Naka-ku Nagoya).  
Statistical analysis 
GraphPad Prism (version 6.01, San Diego, CA) was used to perform paired and unpaired 
t-test, and to calculatòe Pearson correlation coefficient. Results are expressed as mean ± 
SEM, unless otherwise specified. Statistical significance was defined as a p value <0.05. 
Combination analysis was performed using Compusyn software; combinations were 
considered synergistic when combination index (CI) was <1. 
Results 
HIF-1α is overexpressed in CLL cells from TP53dis patients and in TP53 knockout 
lymphoma cell lines  
Expression levels of HIF-1α protein were comparatively evaluated in HD CD19+ cells, and 
in CLL cells isolated from TP53dis and TP53wt samples. As expected, HD CD19+ B cells 
did not express HIF-1α at the baseline normoxic conditions (data not shown). By contrast, 
leukemic cells from CLL patients exhibited detectable cytosolic and nuclear HIF-1α protein 
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(Figure 1A). Interestingly, CLL cells from patients carrying TP53 abnormalities (TP53dis 
CLL cells) had significantly higher amounts of the cytosolic and nuclear fractions of HIF-1α 
subunit, as well as a higher HIF-1A mRNA levels, compared to CLL cells isolated from 
TP53wt cases (TP53wt CLL cells) (Figure 1 A-B). We evaluated an enlarged cohort of 
cases and observed that the association between the expression of HIF-1α and the TP53 
status was not influenced by the IGHV mutational status (Supplemental Figure S1). The 
transcriptional activity of HIF-1α, was evaluated through the expression of selected target 
genes13,15,27. We found a higher expression of GLUT1 and ENO1 in TP53dis CLL cells, 
compared to TP53wt sòamples (Figure 1 C-D). To corroborate the finding of an association 
between HIF-1α expression and TP53 status we exploited cell line models. Interestingly, 
the expression of HIF-1α protein and mRNA was higher in TP53ko Granta-519 and 
Séraphine lymphoma cell lines, compared to the p53wt (Figure 1 E-F). In line with this 
finding, the expression VEGF, GLUT1 and ENO1 was also significantly higher in TP53ko 
than in TP53wt Granta-519 and Séraphine cell lines (Figure 1G).  
To further investigate the link between TP53 and HIF-1α, we performed a GSEA on 
previously published microarray data from tumour cells isolated from 7 TP53dis and 13 
TP53wt cases (geocode GSE18971)28. Data of GSEA cases revealed that the TP53 
abnormalities were associated with an upregulation of a number of genes belonging to the 
“GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP” gene set (Figure 2A). The protein 
ELK3 participates in the transcriptional response to hypoxia and controls the expression of 
several regulators of HIF-1α stability29. Consistently, the baseline expression of ELK3 was 
higher in TP53dis compared to TP53wt CLL cells (Figure 2B).  
Given its role HIF-1α regulation12,30, we also compared pVHL expression in TP53dis and 
TP53wt samples. Notably, CLL cells from TP53dis patients had reduced amounts of pVHL 
compared to TP53wt patients, most likely being responsible of a better stabilization of the 
HIF-1α protein and a repression of its proteasomal degradation in TP53dis cells (Figure 
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2C). As for HIF-1α expression, there were no differences between pVHL levels according 
to the IGHV mutational status (Supplemental Figure S2). These data suggest that TP53 
abnormalities lead to a reduced expression of pVHL and subsequently to an accumulation 
of HIF-1α protein.  
Hypoxia and SC further increase HIF-1α expression in CLL cells from TP53dis and TP53wt 
patients 
We next investigated whether microenvironmental signals, such as oxygen deprivation12 
and the interactions with SC20, had differential effects on HIF-1α according to the TP53 
status of the leukemic cells, also in an attempt to better define the underlying molecular 
mechanisms. To this end, CLL cells were cultured for 48 hours in condition of hypoxia or in 
the presence of SC. Of note, ex vivo culture partially abrogated the TP53-related 
differential expression of HIF-1α observed at the baseline in freshly isolated CLL cells. In 
hypoxia, we observed a marked upregulation of the cytosolic and nuclear fractions of HIF-
1α protein which was independent from the TP53 status (Figure 3A) and was associated to 
a reduced expression of pVHL (Figure 3B), and to an activation of the PI3K/AKT and 
RAS/ERK1-2 pathways (Figures 3 C-F). Consistently, we observed that blocking 
concentration of pharmacologic agents inhibiting ERK1-2 (PD98059) and PI3K 
(LY294002) effectively counteracted the hypoxia-induced HIF-1α upregulation, 
independently from the TP53 status (Figure 3G).  
In line with previous data20, we observed a marked upregulation of the cytosolic and 
nuclear amounts of the HIF-1α, when CLL cells were co-cultured with the SC (Figure 4A). 
SC-induced HIF-1α elevation was not associated to a reduced pVHL expression in 
leukemic cells (Figure 4B), whereas we observed an increased activation of RHOA/RHOA 
kinase (Figures 4 C-D), PI3K/AKT (Figure 4E), andò RAS/ERK1-2 (Figure 4F) signalling 
pathways. As a confirmation, we found that targeted inhibition of ERK1-2, PI3K and RHOA 
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kinase by blocking concentrations of pharmacologic agents (i.e. PD98059, LY294002 and 
Y27632, respectively) effective counteracted SC-induced HIF-1α upregulation (Figure 4G).  
The role of these pathways in modulating HIF-1α overexpression was corroborated by 
titration experiments showing that exposure of TP53dis and TP53wt CLL cells to increasing 
concentrations of PD98059, LY294002 and Y27632 induced a progressive reduction of the 
activity of the targeted kinases, which was associated to a dose-dependent decrease in 
HIF-1α levels (Supplemental Figure S3).  
The selective HIF-1α inhibitor BAY87-2243 has anti-tumour activities in CLL 
In line with the role of HIF-1α as a cells survival promoting factor12, we found a positive 
correlation between the baseline levels of HIF-1A mRNA and the 48-hour viability of CLL 
cells during in vitro culture (Figure 5A). Consistently, the viability of leukemic cells isolated 
from samples characterized by baseline HIF-1A mRNA levels above the median value of 
the entire cohort (HIF-1Ahigh) was significantly higher than the viability of CLL cells 
displaying lower HIF-1A values (HIF-1Alow) (Figure 5B and Supplemental Figure S4). 
Based on these observations and on previous data reporting HIF-1α as a potential 
therapeutic target in CLL17, we evaluated the anti-tumour effect of BAY87-2243, a 
selective inhibitor of HIF-1α. First, we observed that BAY87-2243 effectively inhibited HIF-
1α protein expression at the cytosolic and nuclear level, both in TP53dis and TP53wt CLL 
cells (Figure 5C), also counteracting the HIF-1α upregulation exerted by hypoxia and SC 
(Figures 5 D-E). After 48 hours, BAY87-2243 determined a strong cytotoxic effect toward 
leukemic cells isolated from both patient subsets (Figure 5F and Supplemental Figure S5). 
Of note, the downregulation of HIF-1α was also evident at 24-hour exposure, when cell 
viability was still well preserved, thus confirming that it was determined by a targeted 
inhibitory effect rather than by a consequence of cell death (data not shown). BAY87-2243 
exerted a cytotoxic effect also when TP53dis and TP53wt CLL cells were cultured for 48 
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hours in the presence of extrinsic signals inducing a further upregulation of baseline levels 
of HIF-1α, such as hypoxia (Figure 5G and Supplemental Figure S6) and co-culture with 
SC (Figure 5H and Supplemental Figure S7).  
To further corroborate these data and the ability of BAY87-2243 to exert effective anti-
tumour functions in CLL, we utilized a murine model derived from the transfer of Eµ-TCL1 
leukemic cells into syngeneic mice17. In line with the results reported by Valsecchi et al.17, 
showing that HIF-1α regulates the interaction of CLL cells with the bone marrow (BM) 
microenvironment, we observed that BAY87-2243 significantly reduced BM infiltration by 
leukemic cells, also inducing cytotoxicity in a consistent proportion of CLL cells (Figure 5 I-
K). The anti-tumour effect observed with BAY87-2243 in the BM was not evident in the PB 
and spleen compartments (data not shown), suggesting that in a murine model of 
aggressive and rapidly growing CLL, HIF-1α may serve as a pro-survival factor especially 
for the leukemia reservoir residing in the BM. 
In conclusion, our data indicate that HIF-1α is a pro-survival factor in CLL, which can be 
effectively targeted by the pharmacologic agent BAY87-2243, a specific inhibitor with 
potent anti-tumour effects both in vitro and in vivo. 
BAY87-2243 restores fludarabine sensitivity of TP53dis CLL cells and counteracts the 
protective effect of SC  
We next examined whether BAY87-2243 was also effective in overcoming the intrinsic 
resistance to fludarabine of CLL cells from TP53dis patients9,31–33. As expected, in our 
cohort, the normalized cell viability after 48-hour F-ara-A treatment was significantly higher 
in TP53dis compared to TP53wt CLL cells (Figure 6A). Consistently, we observed that CLL 
cells with a normalized cell viability ≥0.5, arbitrarily considered as fludarabine-resistant, 
were mostly TP53dis and had a significantly higher baseline expression of HIF-1A mRNA 
compared to fludarabine-sensitive cells (i.e. normalized cell viability <0.5) (Figure 6B). 
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Interestingly, BAY87-2243 enhanced the cytotoxicity of fludarabine on TP53dis CLL cells, 
as shown by the significant impairment of cell viability observed after combined treatment 
with BAY87-2243 + fludarabine compared to each compound used as a single agent 
(Figure 6C). The cytotoxic effect exerted by the combination was strongly synergistic 
(CI=0.17) on TP53dis CLL cells and was also evident, although less remarkable, on TP53wt 
CLL cells (Figure 6C and Supplemental Figure S8). Interestingly, we observed that 
combinations consisting of lower concentrations of BAY87-2243 + fludarabine were 
capable to induce significant reductions of the cell viability compared to each drug used as 
a single agent, and this effect was particularly evident in the TP53dis CLL subset (Figure 
6D). The cytotoxic activity of the combinations was also strongly synergistic as shown by 
data on CI (Supplemental Figure S9). Notably, the significantly higher cytotoxicity of the 
combination BAY87-2243 + fludarabine was maintained even when both TP53dis and 
TP53wt CLL cells were cultured under hypoxia (Supplemental Figures S10 A-B) or in the 
presence of SC (Supplemental Figures S10 C-D).  
These results indicate that BAY87-2243 and fludarabine synergistically eliminate primary 
CLL cells, and that their effect was maintained even in the presence of HIF-1α inducing 
factors that recapitulate the BM niche microenvironment. 
The combination of BAY87-2243 and ibrutinib exerts a synergistic cytotoxic effect on CLL 
cells 
Previously reported data indicate that TP53-mutated CLL cells have a lower sensitivity to 
ibrutinib cytotoxicity in vitro34 and that ibrutinib-induced apoptosis is significantly reduced in 
conditions of hypoxia19. Therefore, we hypothesized that the combination of a HIF-1α 
inhibitor and ibrutinib may represent a potentially attractive next step for patients carrying 
TP53 abnormalities, who are characterized by constitutively higher levels of HIF-1α. Our 
results show that the combination of BAY87-2243 + ibrutinib determined a significant 
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impairment in the viability of TP53dis and TP53wt CLL cells, compared to each compound 
used as a single agent and was very strongly synergistic (Figure 7A and Supplemental 
Figure S11). Interestingly, similar effects were observed also with lower concentrations of 
both agents (Figure 7B and Supplemental Figure S12). Notably, the combination BAY87-
2243 + ibrutinib exerted a significantly higher cytotoxic effect compared to each single 
compound even when CLL cells from both TP53dis and TP53wt samples were cultured in 
the presence of SC (Figure 7C). 
Overall, these data demonstrate that BAY87-2243 exerts a compelling synergistic effect 
with ibrutinib, thus providing the rationale for future clinical translation.  
Discussion 
 
In this study, we investigated the expression and regulation of HIF-1α in TP53dis CLL cells, 
and its potential role as a therapeutic target. We found that CLL cells carrying TP53 
abnormalities express significantly higher baseline levels of HIF-1α and have increased 
HIF-1α transcriptional activity compared to TP53wt cells. Regardless of the TP53 status, 
the resting levels of HIF-1α are susceptible to further upregulation by microenvironmental 
stimuli, such as hypoxia and SC. Our data show that HIF-1α is a suitable therapeutic 
target, whose inhibition induces a strong cytotoxic effect, capable also of reversing the in 
vitro fludarabine resistance of TP53dis CLL cells and of exerting synergistic effects with 
ibrutinib. 
Hypoxia has a detrimental role in the pathobiology of several solid and hematologic 
tumours35,36. The identification of new potential targets in CLL is certainly important for 
high-risk patients, for which an effective cure is still lacking, and in addition, the 
development of new therapies might be effective in a broader setting of B 
lymphoproliferative disorders. 
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It has been previously reported that HIF-1α levels vary considerably among CLL patients 
and that its overexpression is a predictor of a poor survival17,37. In line with observations 
made in solid tumours, where p53 promotes the ubiquitination and proteasomal 
degradation of the HIF-1α subunit in hypoxia12,22, we postulated that abnormalities of the 
TP53 gene might have an influence on the regulation of HIF-1α in CLL cells. To the best of 
our knowledge, this is the first study examining the differential expression and 
transcriptional activity of HIF-1α in patients with TP53-deficient CLL, also uncovering new 
mechanisms for HIF-1α modulation in leukemic cells. Our data show that the high-resting 
levels of HIF-1α detected in TP53dis samples associate both to an increased transcription, 
as shown by the higher HIF-1A mRNA levels, and to a decreased degradation, as shown 
by the higher baseline expression of ELK3 and by the lower pVHL amounts.  
We next investigated the cellular pathways implicated in HIF-1α regulation mediated by 
extrinsic factors. Hypoxia-induced HIF-1α upregulation is not only due to a reduced pVHL-
mediated protein degradation, which is a well-known mechanism in condition of oxygen 
deprivation, but also to an increased activation of RAS/ERK1-2 and PI3K/AKT signalling 
pathways. By contrast, pVHL expression in leukemic cells is not affected by SC, which 
instead activate the RAS/ERK1-2, RHOA/RHOA kinase and PI3K/AKT intracellular 
pathways, thus leading to HIF-1α overexpression. These results endorse recent data that 
implicate a number of paracrine factors in the transcriptional and translational regulation of 
HIF-1α in different tumour models38.  
Previous data have suggested that HIF-1α targeting is a promising therapeutic strategy in 
CLL, potentially capable of synergizing with chemotherapeutic agents. The only HIF-1α 
inhibitor that has been preclinically tested in CLL is EZN-2208 - a topoisomerase I inhibitor 
that has also shown to downmodulate HIF-1α17. We therefore tested, BAY87-2243, a more 
selective HIF-1α inhibitor that has already shown in vivo anti-tumour efficacy in a lung 
tumour model, without any signs of toxicity39. Interestingly, BAY87-2243 demonstrated a 
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direct cytotoxicity towards leukemic cells isolated from CLL patients, and this effect was 
independent from the TP53 status. As far as we know, this is the first evidence of the anti-
tumour activity of BAY87-2243 in hematologic tumours and particularly in CLL. 
Patients with CLL and TP53 abnormalities are intrinsically resistant to fludarabine-based 
chemotherapy regimens9,31–33,40,41. Supported by our data demonstrating i) higher baseline 
levels of HIF-1α in fludarabine-resistant CLL cells and ii) a further upregulation of HIF-1α 
after exposure to hypoxia and SC, we investigated the ability of BAY87-2243 to overcome 
both intrinsic (i.e. TP53-related) and inducible (i.e. SC-induced) resistance to fludarabine. 
Our data show that BAY87-2243 potently synergizes with fludarabine in vitro, and that their 
combined cytotoxic effect was especially evident in TP53dis samples. Interestingly, HIF-1α 
inhibition was also effective in overcoming the TP53-independent fludarabine-resistance 
induced by extrinsic factors recapitulating the BM microenvironment.  
Since HIF-1α critically regulates the interactions of CLL cells with the BM stroma17, the 
cytotoxic effects exerted by BAY87-2243 in culture systems mimicking the tumour niche 
could be in part the result of a perturbation of molecular circuits triggered by 
microenvironmental stimuli, which are implicated in cell survival and drug resistance. Data 
showing that hypoxia and SC induce HIF-1α overexpression support the hypothesis that, 
within the tumour niche, leukemic cells become highly dependent on its pro-survival effect. 
In line with this assumption, we found that treatment with BAY87-2243 induced a marked 
reduction of leukemic infiltration and a parallel increase in the proportion of apoptotic 
leukemic cells in the BM of a CLL transplantable model derived from the Eµ-TCL1 
transgenic mice. Of note, the inhibition of HIF-1α may have beneficial effects also on the 
non-leukemic milieu. Recent data have shown that infiltration by CLL cells into BM could 
result in tissue-site hypoxia, causing i) increased expression of HIF-1α in hematopoietic 
progenitors, which leads to an impaired haematopoiesis and a reduced output of innate 
immune cells into the blood, and ii) impaired functions of different immune cells 
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subsets19,42. Overall, these evidences endorse the concept of HIF-1α inhibition as a very 
promising therapeutic strategy in CLL.  
In the era of new targeted treatments, ibrutinib has determined a dramatic change in the 
therapeutic landscape and has become the standard of care for the majority of CLL 
patients43–45. However, i) ibrutinib is not suitable for all CLL patients and may have limited 
availability in several Countries, ii) complete responses are infrequent, and indefinite drug 
administration is usually needed to maintain a clinical response, and iii) the development 
of ibrutinib resistance in CLL cells has been demonstrated46,47. Even more importantly, 
TP53dis CLL patients show a suboptimal long-term response to ibrutinib48, and TP53-
mutated CLL cells have a lower sensitivity to ibrutinib cytotoxicity in vitro34. Since our data 
show that TP53dis samples are characterized by higher levels and function of HIF-1α, 
which is a crucial target to overcome the constitutive and inducible drug resistance of CLL 
cells, we hypothesized that the combination of BAY87-2243 and ibrutinib might be an 
appealing approach for in vitro testing. We found that dual targeting of HIF-1α alongside 
BTK function produces a synergistic cytotoxic activity towards primary CLL cells, also in 
the presence of TP53 abnormalities, thus suggesting the possibility of improving ibrutinib 
efficacy through this novel therapeutic association.  
Overall, our data indicate that HIF-1α is overexpressed in CLL cells, especially in the 
presence of TP53 aberrations, and that is susceptible of further upregulation by 
microenvironmental stimuli. From the translational standpoint, the pharmacologic 
compound BAY87-2243, a selective inhibitor of HIF-1α, displays potent anti-tumour 
properties and warrants further pre-clinical evaluation in this disease setting, also in 
combination with other therapies. Indeed, on one hand the synergism of BAY87-2243 and 
fludarabine may provide the rationale for future clinical application in Countries with limited 
access to ibrutinib, particularly for the treatment of high-risk patients carrying TP53 
abnormalities. On the other hand, BAY87-2243 coupled with ibrutinib may offer a rational 
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combination to increase the proportion of minimal residual disease negative remissions, 
thus reducing the development of CLL clones with resistance mutations.  
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Figure Legends  
Figure 1. HIF-1α is overexpressed and more active in primary cells isolated from 
patients with CLL and in lymphoma cell lines carrying a TP53 disruption 
The expression of HIF-1α and HIF-1α target genes was measured in TP53dis and TP53wt 
CLL cells and in lymphoma TP53wt and TP53ko cell lines. (A) WB analysis for HIF-1α 
protein expression in freshly isolated TP53dis and TP53wt CLL cells. A representative blot is 
shown with relative Unique Patient Numbers (UPN) and cumulative band intensity data 
obtained from the analysis of 17 TP53wt and 15 TP53dis CLL patients. Box plots represent 
median value and 25%-75% percentiles, whiskers represent minimum and maximum 
values of band intensity for each group. (B-D) RT-PCR analysis of HIF-1A, and its target 
genes GLUT1 and ENO1 expression levels in TP53dis and TP53wt CLL cells. (E) WB 
analysis for HIF-1α protein expression in the TP53wt and TP53ko Granta-519 and 
Séraphine cell lines. A representative blot of 3 independent experiments is shown. (F) RT-
PCR analysis of HIF-1A in the TP53wt and TP53ko Granta-519 and Séraphine cell lines. 
(G) RT-PCR analysis of VEGF, GLUT1 and ENO1 in the TP53wt and TP53ko Granta-519 
and Séraphine cell lines showed a significantly higher expression level of all analysed 
genes in TP53ko samples. In panels B, C and D box and whiskers plots represent median 
values and 25%-75% percentiles, whiskers represent minimum and maximum values for 
each group. In panels F and G, bar graphs represent mean results obtained from 3 
experiments together with SEM. **** p<0.0001, *** p<0.001, ** p<0.01 and *p<0.05.  
Figure 2. TP53dis CLL cells show an upregulation of several genes involved in 
response to hypoxia and express reduced levels of pVHL. (A) GSEA on CLL cells 
from TP53dis and TP53wt patients. The plot of the Enrichment Score (ES) versus the gene 
list index and a portion of the corresponding heatmap highlighting the relative expression 
of gene members belonging to the “GROSS_HYPOXIA_VIA_ELK3_AND_HIF1A_UP” 
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gene set are depicted. 54 out of 126 genes from the gene set were significantly 
upregulated in the TP53dis cohort of patients compared to the TP53wt cohort. (B) WB for 
ELK3 baseline expression in TP53dis and TP53wt CLL cells. A representative blot is shown 
with relative UPN and cumulative band intensity data obtained from the analysis of 9 
TP53wt and 6 TP53dis CLL patients. (C) WB for pVHL baseline expression in TP53dis and 
TP53wt CLL cells. A representative blot is shown with relative UPN and cumulative band 
intensity data obtained from the analysis of 15 TP53wt and 12 TP53dis CLL patients. Box 
plots represent median value and 25%-75% percentiles, whiskers represent minimum and 
maximum values of band intensity for each group. **** p<0.0001, and *p<0.05.  
Figure 3. Hypoxia further increases HIF-1α expression in TP53dis and TP53wt CLL 
cells via the PI3K/AKT and RAS/ERK1-2 signalling pathways.  
Primary CLL cells were cultured for 48 hours under normoxic and hypoxic conditions. (A, 
B) WB analyses detected a higher amount of cytosolic and nuclear HIF-1α and lower 
amount of pVHL in TP53dis and TP53wt CLL cells cultured in hypoxia (H) compared to 
normoxia (N). (C, D) Immuno-enzymatic measurement showed that RHOA-GTP and 
RHOA kinase activities were unaffected by hypoxia. (E, F) WB analyses for AKT, RAS and 
ERK1-2. TP53dis and TP53wt CLL cells had higher expression of the active form of AKT 
[p(Ser 473)AKT],  RAS (RAS-GTP) and ERK1-2 [p(Thr202/Tyr204, Thr185/Tyr187]ERK1-
2) in hypoxia compared to normoxia. (G) WB analyses for HIF-1α. The targeting of ERK1-2 
with 10 μM PD98059 (PD) and of PI3K with 10 µM LY294002 (LY) reduced HIF-1α 
expression in CLL cells, both in hypoxia and normoxia, and independently from the TP53 
status. In panel A, results are from 2 representative cases of 7 for TP53wt patients and 2 
representative cases of 5 for TP53dis patients. Representative blots are shown with relative 
UPN and cumulative band intensity data. Box plots represent median values and 25%-
75% percentiles, whiskers represent minimum and maximum values of band intensity for 
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each group. In panels B, E and F results are from 1 representative experiment of 4 for 
TP53wt patients and 1 representative experiment of 3 for TP53dis patients. Bar graphs 
represent mean values together with SEM. In panels C and D, multiple line graphs 
represent individual data values for the same sample in each condition. In panel G results 
are from 1 representative experiment of 3 for TP53wt patients and 1 representative 
experiment of 3 for TP53dis patients. Vertical lines have been inserted to indicate 
repositioned gel lanes. **** p<0.0001, ** p<0.01 and *p<0.05.  
Figure 4. SC increase HIF-1α expression in TP53dis and TP53wt CLL cells via 
PI3K/AKT, RAS/ERK1-2 and RHOA/RHOA kinase signalling pathways.  
Primary CLL cells were cultured for 48 hours in the presence and in absence of M2-10B4 
SC. (A, B) WB analyses for HIF-1α and pVHL. SC upregulated the cytosolic and nuclear 
expression of HIF-1α but did not affect pVHL expression in TP53dis and TP53wt CLL cells. 
(C, D) Immuno-enzymatic measurement showed that the co-culture with SC increased 
RHOA-GTP and RHOA kinase activities in TP53dis and TP53wt CLL cells. (E, F) WB 
analyses for AKT, RAS and ERK1-2. Higher amount of the active form of AKT [p(Ser 
473)AKT], RAS (RAS-GTP) and ERK1-2 [p(Thr202/Tyr204, Thr185/Tyr187)ERK1-2] were 
detectable in both TP53wt and TP53dis CLL cells cultured with SC. (G) WB analyses for 
HIF-1α. The targeting of ERK1-2 with 10 μM PD98059 (PD), 10 μM Y27632 (Y276) and of 
PI3K with 10 μM LY294002 (LY) reduced HIF-1α expression in CLL cells, both in presence 
and in the absence of SC, regardless of the TP53 status. In panel A, results are from 2 
representative cases of 10 for TP53wt patients and 2 representative cases of 4 for TP53dis 
patients. Representative blots are shown, together with UPN and cumulative band 
intensity data. Box plots represent median values and 25%-75% percentiles, whiskers 
represent minimum and maximum values of band intensity for each group. In panels B and 
G, results are from 1 representative experiment of 3 for TP53wt patients and 1 
representative experiment of 3 for TP53dis patients. In panels C and D, multiple line graphs 
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represent individual data values for the same sample in each condition. In panels E and F, 
results are from 1 representative experiment of 5 for TP53wt patients and 1 representative 
experiment of 4 for TP53dis patients. Bar graphs represent mean values together with 
SEM. Vertical lines have been inserted to indicate repositioned gel lanes. **** p<0.0001, 
*** p<0.001, ** p<0.01 and *p<0.05.  
Figure 5. HIF-1α promotes CLL cells survival and its inhibition exerts a direct 
cytotoxicity, also in the presence of HIF-1α inducing microenvironmental stimuli. (A) 
Correlation of HIF-1A gene expression and 48-hour cell viability of CLL cells as 
determined by Annexin V/propidium iodide assay. (B) The median value of HIF-1A mRNA 
expression of a cohort of 25 CLL samples was selected as the cut-off to identify HIF-1Ahigh 
and HIF-1Alow CLL cells. HIF-1Ahigh showed significantly higher 48-hour cell viability 
compared to HIF-1Alow CLL cells. (C) WB analyses for HIF-1α. The exposure to 1 µM 
BAY87-2243 (BAY) for 48 hours reduced the cytosolic and nuclear amount of HIF-1α in 
CLL cells isolated from both TP53wt and TP53dis patient subsets. A representative blot is 
shown, together with UPN and cumulative band intensity data obtained from the analysis 
of 14 TP53wt and 4 TP53dis CLL patients. Box plots represent median value and 25%-75% 
percentiles, whiskers represent minimum and maximum values of band intensity for each 
group. (D, E) Primary CLL cells were exposed to 1 µM BAY for 48 hours under normoxic 
and hypoxic conditions, in the absence and in presence of M2-10B4 SC, and evaluated for 
HIF-1α expression by WB. BAY87-2243 was able to lower HIF-1α expression in CLL 
cultured in normoxic and hypoxic conditions, and in the absence or presence of SC, 
independently from the TP53 status. (F-H) Cell viability of TP53dis and TP53wt CLL cells 
exposed for 48 hours to 1 μM BAY87-2243, under normoxia and hypoxia, or in co-culture 
with SC. The treatment with BAY87-2243 determined a significant decrease in the viability 
of TP53wt and TP53dis CLL cells, compared to untreated controls, both in normoxia and 
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hypoxia. After exposure to SC, BAY87-2243 significantly reduced the viability of TP53dis 
and TP53wt CLL cells, not completely overcoming the SC protective effect. In blot 
representations, vertical lines have been inserted to indicate repositioned gel lanes. (I) 
Scheme of the in vivo experiment with mice transplanted with the Eµ-TCL1-derived 
leukemia. (J) Percentage of leukemic cells (CD19+) in the BM of mice transplanted with 
the Eµ-TCL1-derived leukemia, treated with BAY87-2243, and euthanized as in panel I. 
(K) Percentage of AnnV leukemic cells (CD19+) in the BM of mice transplanted with Eµ-
TCL1-derived leukemia, treated with BAY87-4432, and euthanized as in panel I. In panel A 
data are represented by a scatter plot. In panels J and K data are represented as bee-
swarm plots. In panel B box and whiskers plots represent median values and 25%-75% 
percentiles, whiskers represent minimum and maximum values for each group. In panel D, 
results are from 1 representative experiment of 3 for TP53wt patients and 1 representative 
experiment of 3 for TP53dis patients. In panel E, results are from 1 representative 
experiment of 7 for TP53wt patients and 1 representative experiment of 4 for TP53dis 
patients. In panels F, G and H box and whiskers plots represent median values and 25%-
75% percentiles, whiskers represent minimum and maximum values for each group, 
together with all points. **** p<0.0001, *** p<0.001, ** p<0.01 and *p<0.05. 
Figure 6. HIF-1A mRNA is overexpressed in fludarabine-resistant CLL cells and HIF-
1α inhibition is capable of restoring fludarabine sensitivity. (A) Normalized cell 
viability (i.e. the ratio between the percentage of AnnV/PI negative CLL cells cultured in 
the presence of F-ara-A and the percentage of AnnV/PI negative CLL cells left untreated) 
of TP53dis and TP53wt CLL cells exposed for 48 hours to 10 μM F-ara-A. (B) A normalized 
cell viability of 0.5 was selected as the cut-off value to identify fludarabine-resistant (i.e. 
normalized cell viability ≥0.5) and fludarabine-sensitive (i.e. normalized cell viability <0.5) 
CLL cells. Fludarabine-resistant CLL cells showed significantly higher baseline levels of 
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HIF-1A mRNA compared to fludarabine-sensitive. Eight out of 10 (80%) fludarabine-
resistant samples derived from TP53dis patients, and 13 out of 14 (93%) fludarabine-
sensitive samples derived from TP53wt patients. (C) Normalized cell viability of TP53dis and 
TP53wt CLL cells exposed for 48 hours to 1 μM BAY87-2243 (BAY) and/or 10 μM F-ara-A. 
The combination BAY87-2243 + F-ara-A (striped pattern) determined a significant 
decrease in the viability of TP53wt and TP53dis CLL cells, compared to each compound 
used as single agent and to untreated controls. (D) Heatmaps showing normalized viability 
after 48-hour treatment with BAY87-2243 + fludarabine as single agents or in combination, 
used at different concentrations. Asterisks indicate the combinations which determined a 
significant reduction in cell viability compared to each single agent, at the corresponding 
concentration. In panels A and C, box plots represents median values and 25%-75% 
percentiles, whiskers represent minimum and maximum values for each group, together 
with all points. In panel B data are represented as bee-swarm plot. **** p<0.0001, *** 
p<0.001, ** p<0.01 and *p<0.05. 
Figure 7. BAY87-2243 plus ibrutinib combinations exert synergistic cytotoxic effects 
and is effective in impairing CLL cells viability in the presence of SC. (A) Normalized 
48-hour viability of TP53dis and TP53wt CLL cells exposed to 1 μM BAY87-2243 (BAY) and 
10 μM ibrutinib, used as single agents or in combination (striped pattern). Box plots 
represent median value and 25%-75% percentiles, whiskers represent minimum and 
maximum values for each group, together with all points. (B) Heatmaps showing 
normalized viability after 48-hour treatment with BAY87-2243 + ibrutinib as single agents 
or in combination, used at different concentrations. Asterisks indicate the combinations 
which determined a significant reduction in cell viability compared to each single agent, at 
the corresponding concentration. (C) Normalized 48-hour viability of TP53dis and TP53wt 
CLL cells exposed to 1 μM BAY87-2243 (BAY) and 10 μM ibrutinib, used as single agents 
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or in combination (striped pattern), in co-culture with M2-10B4 SC. Box plots represent 
median value and 25%-75% percentiles, whiskers represent minimum and maximum 
values for each group, together with all points. *** p<0.001, ** p<0.01 and *p<0.05. 
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Supplemental Methods 
Cells preparation and culture  
PBMC were separated using Ficoll-Hypaque (Sigma-Aldrich) and stained with anti-CD19 
PerCP Vio700 and anti-CD5-APC antibodies (Miltenyi Biotec, Bologna, Italy). When the 
CD19+/CD5+ cells were < 90%, CLL cells were purified by negative selection and cultured 
in RPMI-1640 medium with 10% of fetal bovine serum (FBS) and penicillin/streptomycin. B 
lymphocytes from healthy donors were purified by positive selection using anti-CD19 micro 
beads (Miltenyi Biotec). Del(17p) was assessed by fluorescence in situ hybridization and 
the presence of TP53 gene mutations was evaluated by Sanger sequencing. 
Immunoglobulin heavy chain variable region gene (IGHV) mutational status was assessed 
as already described1. Cell lines used in the experiments (i.e. Séraphine, Granta-519 and 
M2-10B4) were maintained in RPMI-1640 or DMEM medium with 10% fetal bovine serum, 
glutamine and antibiotics at 37 °C, 5% CO2. A humidified hypoxia incubator chamber was 
used for hypoxic cultures.  
Antibodies used for flow cytometry 
Two- and three-color flow cytometry was performed with FACSCalibur and CELLQuest 
software (Becton Dickinson, Mountain View, CA) and with BD Accuri C6 flow cytometer 
(BD Bioscences). Data were analyzed with FlowJo software (Tree Star, Inc, Ashland, OR). 
Antibodies used for flow cytometry were: anti-CD19-PE (BD Biosciences, San José, CA), 
anti-CD19-PerCP Vio700 (Miltenyi Biotec), anti-CD5-APC (Miltenyi Biotec).  
 Western blot analysis 
Cytosolic and nuclear protein extracts were obtained using the Nuclear Extract Kit (Active 
Motif, La Hulpe) following the manufacturer’s instructions. Lysates were resolved by 
SDS‐PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). The 
following antibodies were used: anti-HIF-1α (BD Biosciences, San José, CA), anti-ELK3 
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(Sigma Aldrich); anti-pVHL (EuroClone Spa, Milano); anti p(Thr202/Tyr204, 
Thr185/Tyr187)-ERK1–2 (Millipore, Bedford, MA); anti-ERK1-2 (Millipore); anti-RAS 
(Millipore); anti-RHOA (Santa Cruz Biotechnology Inc., Santa Cruz, CA) antibody anti-
p(Ser 473)AKT (Millipore); anti-AKT (Millipore); anti-ACTIN (Sigma Aldrich), anti-GAPDH, 
anti-TUBULIN and anti-TATA-box binding protein (TBP) (Santa Cruz Biotechnology Inc.) 
used as control of equal protein loading for cytosolic and nuclear fractions, followed by the 
secondary peroxidase-conjugated antibodies (Bio-Rad, Hercules, CA). To exclude nuclei-
cytosol contamination, we verified that GAPDH and TBP were always undetected in 
nuclear and cytosolic fractions, respectively (not shown). Blot images were acquired with a 
ChemiDocTM Touch Imaging System device (Bio-Rad Laboratories). Densitometric 
analysis was performed with the ImageJ software (NIH, Bethesda, MD). 
RNA extraction and quantitative real-time PCR (qRT-PCR)  
Total RNA was extracted and reverse transcribed as described2. The qRT-PCR was 
performed with the iTaqTM Universal SYBR® Green Supermix (Bio-Rad). The primer 
sequences were designed with the qPrimerDepot software 
(http://primerdepot.nci.nih.gov/). The primer sequences were: HIF-1A: 5’- 
GGCTGCATCTCGAGACTTT-3’: 5’-GAAGACATCGCGGGGAC; ENO1: 5’- 
GCTCCGGGACAATGATAAGA-3’, 5’- TCCATCCATCTCGATCATCA-3’, GAPDH: 5′-
GAAGGTGAAGGTCGGAGT-3′, 5′-CATGGTGGAAT CATATTGGAA-3′; VEGF: 5’-
ATCTTCAAGCCATCCTGTGTGC-3’, 5’-GCTCACCGCCTCGGCTTGT-3’. The 
comparative CT method was used to calculate HIF-1α, GLUT1, ENO1 and VEGF 
expression relative to the GAPDH product, used as a housekeeping gene, with the Bio-
Rad Software Gene Expression Quantitation. 
RAS and RHOA activity 
The isoprenylated membrane-associated RAS or RHOA proteins and the non-
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isoprenylated cytosolic forms were detected as previously described2. Total RAS and 
RHOA proteins were analyzed by WB; Briefly, the GTP-bound fraction, taken as an index 
of active G-proteins was measured, using a pull-down assay (with the RAF-1-GST fusion 
protein, agarose beads-conjugates, Millipore, Bedford, MA) and an ELISA assay (with the 
G-LISA™ RHOA Activation Assay Biochem Kit, Cytoskeleton Inc, Denver, CO), 
respectively.  
Kinase inhibitors titration and kinase activity 
For kinase inhibitors titration experiments we exposed CLL cells (106/mL) for 48 hours to 
PD98059, LY249002 and Y27632 at indicated increasing concentrations. ERK1-2, AKT 
and RHOA kinases activity was measured by spectrophotometric methods, using the 
CycLex RHO Kinase Assay Kit (CycLex, Nagano), the MAP Kinase/Erk Assay Kit 
(Millipore, Bedford, MA) and the AKT Kinase Activity Assay Kit (Abcam, Cambridge), as 
per manufacturer’s instructions.  
Cell viability assay 
Cell viability was evaluated by flow cytometry using with Annexin-V/Propidium Iodide (Ann-
V/PI) staining with the MEBCYTO-Apoptosis Kit (MBL Medical and Biological Laboratories, 
Naka-ku Nagoya). Normalized cell viability was arbitrarily defined as the ratio between the 
percentage of AnnV-/PI- CLL cells cultured in the presence of F-ara-A and the percentage 
of AnnV-/PI- CLL cells that were left untreated. CLL cells characterized by a normalized 
cell viability ≥0.5 were defined as fludarabine-resistant, otherwise, CLL cells were 
considered fludarabine-sensitive. 
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Table 1. Summary of genetic patient characteristics and treatment status 
 
Unique 
Patient 
Number 
(UPN) 
TP53 subset 
del(17)p, 
clone size in 
%  
TP53mut, allele 
frequency in % 
IGHV 
mutational 
status 
Previous 
Treatment 
UPN01 TP53dis neg mut, 84 M y 
UPN02 TP53dis 42 mut, 83 UM y 
UPN03 TP53dis 85 mut, 83 UM n  
UPN04 TP53dis 80 mut, 79 UM n  
UPN05 TP53dis neg mut, 75 UM y 
UPN06 TP53dis 79 mut, 86 M n 
UPN07 TP53dis neg mut, nd UM y 
UPN08 TP53dis nd mut, nd M nd 
UPN09 TP53dis 87 mut, 81 UM n 
UPN10 TP53dis neg mut, 88 M y 
UPN11 TP53dis 69 mut, 61 UM y 
UPN12 TP53dis neg mut, 36 M n 
UPN13 TP53dis neg mut, 50 M n 
UPN14 TP53dis 24 mut, 37 UM y 
UPN15 TP53dis monosomy 17 mut, 50 UM y 
UPN16 TP53dis 96 mut, 67 nd n 
UPN17 TP53dis neg mut, 50 UM y 
UPN18 TP53dis 53 mut, 31 UM n 
UPN19 TP53dis 20 mut, 92 UM y 
UPN20 TP53dis 88 nd UM n 
UPN21 TP53dis 21 mut, 25 UM n 
UPN22 TP53dis 46 mut, 51 UM y 
UPN23 TP53dis 70 nd nd y 
UPN24 TP53dis neg mut, 34 M y 
UPN25 TP53dis 12 mut, 12 UM y 
UPN26 TP53dis neg mut, nd M y 
UPN27 TP53dis 82 mut, nd M n 
UPN28 TP53dis 80 mut, 63 UM y 
UPN29 TP53dis 68 mut, 75 UM y 
UPN30 TP53dis nd mut, 73 nd n 
UPN31 TP53dis 69 mut, 64 UM n 
UPN32 TP53dis neg mut, nd UM y 
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UPN33 TP53dis 43 mut, 25 M nd 
UPN34 TP53dis neg mut, nd UM n 
UPN35 TP53dis 91 wt M n 
UPN36 TP53dis 59 wt nd n 
UPN37 TP53dis 50 wt UM y 
UPN38 TP53dis 50 wt UM y 
UPN39 TP53dis 46 wt M y 
UPN40 TP53dis 45 wt M n 
UPN41 TP53wt neg wt M y 
UPN42 TP53wt neg wt M n 
UPN43 TP53wt neg wt UM n 
UPN44 TP53wt neg wt UM n 
UPN45 TP53wt neg wt M y 
UPN46 TP53wt neg wt M y 
UPN47 TP53wt neg wt M y 
UPN48 TP53wt neg wt UM n 
UPN49 TP53wt neg wt UM n 
UPN50 TP53wt neg wt M n 
UPN51 TP53wt neg wt UM n 
UPN52 TP53wt neg wt UM y 
UPN53 TP53wt neg wt UM n 
UPN54 TP53wt neg wt UM n 
UPN55 TP53wt neg wt UM n 
UPN56 TP53wt neg wt M n 
UPN57 TP53wt neg wt UM n 
UPN58 TP53wt neg wt UM n 
UPN59 TP53wt neg wt M n 
UPN60 TP53wt neg wt UM y 
UPN61 TP53wt neg wt M n 
UPN62 TP53wt neg wt M n 
UPN63 TP53wt neg wt M y 
UPN64 TP53wt neg wt UM n 
UPN65 TP53wt neg wt UM n 
UPN66 TP53wt neg wt UM n 
UPN67 TP53wt neg wt M n 
UPN68 TP53wt neg wt M n 
UPN69 TP53wt neg wt UM n 
UPN70 TP53wt neg wt nd n 
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UPN71 TP53wt neg wt M y 
UPN72 TP53wt neg wt UM n 
UPN73 TP53wt neg wt UM n 
UPN74 TP53wt neg wt M n 
UPN75 TP53wt neg wt M n 
UPN76 TP53wt neg wt UM n 
UPN77 TP53wt neg wt UM n 
UPN78 TP53wt neg wt M n 
UPN79 TP53wt neg wt M n 
UPN80 TP53wt neg wt UM n 
UPN81 TP53wt neg wt M y 
UPN82 TP53wt neg wt M n 
UPN83 TP53wt neg wt M n 
UPN84 TP53wt neg wt M n 
UPN85 TP53wt neg wt nd n 
UPN86 TP53wt neg wt UM n 
UPN87 TP53wt neg wt UM n 
UPN88 TP53wt neg wt M n 
UPN89 TP53wt neg wt M n 
UPN90 TP53wt neg wt UM n 
UPN91 TP53wt neg wt nd n 
UPN92 TP53wt neg wt UM n 
UPN93 TP53wt neg wt UM n 
UPN94 TP53wt neg wt nd n 
UPN95 TP53wt neg wt UM n 
UPN96 TP53wt neg wt M n 
UPN97 TP53wt neg wt UM n 
UPN98 TP53wt neg wt UM y 
UPN99 TP53wt neg wt UM n 
UPN100 TP53wt neg wt UM y 
UPN101 TP53wt neg wt nd n 
UPN102 TP53wt neg wt M n 
Abbreviations 
Del(17)p chromosome 17p13 deletion 
  neg negative, <10% del(17p) 
  TP53mut TP53 gene mutation 
  mut presence of TP53 gene mutation 
  wt wild type, absence of TP53 gene mutation 
 
nd not determined 
   IGHV Immunoglobulin heavy chian variable region genes 
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M IGHV mutated 
   UM IGHV unmutated 
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Supplemental Figures 
Supplemental Figure 1 
 
 
Figure S1. The association between HIF-1α expression and the TP53 status is not 
influenced by the IGHV mutational status. The expression of HIF-1α was measured in 
TP53wt and TP53dis CLL cells, accounting for the IGHV mutational status. TP53wt CLL 
included 8 IGHV M and 9 IGHV UM samples, and TP53dis CLL included 5 IGHV M and 8 
IGHV UM samples. A representative blot is shown, together with Unique Patients Number 
(UPN) and cumulative band intensity data obtained from the analysis of the four subsets 
(i.e. TP53wt/IGHV M, TP53wt/IGHV UM, TP53dis/IGHV M and TP53dis/IGHV UM CLL 
patients). Box plots represent median values and 25%-75% percentiles, whiskers 
represent minimum and maximum values of band intensity for each group. Vertical lines 
have been inserted to indicate repositioned gel lanes. **** p<0.0001, *** p<0.001, ** 
p<0.01.  
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Supplemental Figure 2 
 
Figure S2. The expression of pVHL is not influenced by IGHV mutational status.  
The expression of pVHL was measured in TP53wt and TP53dis CLL cells, accounting for the 
IGHV mutational status. TP53wt CLL included 9 IGHV M and 6 IGHV UM samples, and 
TP53dis CLL included 6 IGHV M and 6 IGHV UM samples. A representative blot is shown, 
together with UPN and cumulative band intensity data obtained from the analysis of the 
four subsets. Box plots represent median value and 25%-75% percentiles, whiskers 
represent minimum and maximum values of band intensity for each group. Vertical lines 
have been inserted to indicate repositioned gel lanes. **** p<0.0001, ** p<0.01.  
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Supplemental Figure 3 
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Figure S3. Increasing concentrations of ERK1-2, PI3K or RHOA kinase inhibitors 
determine a progressive reduction of HIF-1α levels. Primary CLL cells were cultured 
for 48 hours in the presence of increasing concentration of PD98059 (PD, 0.01 µM, 0.1 
µM, 1 µM or 10 µM) (A), LY294002 (LY, 0.01 µM, 0.1 µM, 1 µM or 10 µM) (B) or Y27632 
(Y276 0.01 µM, 0.1 µM, 1 µM or 10 µM) (C). WB analyses of HIF-1α protein expression for 
1 TP53wt and 1 TP53dis representative CLL patient, together with UPN and the 
corresponding cumulative band intensity data, are shown. ERK1-2, AKT and RHOA kinase 
activities were evaluated by an immunomediated assay and are shown by bar graphs on 
the right.  
 
 
 
 
 
 
 
 
 
 
 
 
 
GRIGGIO V et al   HIF-1α IN TP53-DISRUPTED CLL CELLS 
14 
 
Supplemental Figure 4 
 
Figure S4. Viability of HIF-1Ahigh and HIF-1Alow CLL cells. Representative flow 
cytometry analysis (relative UPN indicated) of AnnV/PI expression on HIF-1Ahigh and HIF-
1Alow CLL cells after 48-hour culture in medium. CLL cells isolated from HIF-1Ahigh 
samples had a significantly higher viability than CLL cells isolated HIF-1Alow samples.  
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Supplemental Figure 5 
 
Figure S5. Viability of TP53wt and TP53dis CLL cells exposed to BAY87-2243. 
Representative flow cytometry analysis (relative UPN indicated) of AnnV/PI expression on 
TP53wt and TP53dis CLL cells exposed to 1 µM BAY87-2243 (BAY) or left untreated for 48 
hours. BAY87-2243 determined a direct cytotoxic effect toward leukemic cells isolated 
from both patient subsets.  
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Supplemental Figure 6 
 
Figure S6. Viability of TP53wt and TP53dis CLL cells exposed to BAY87-2243 under 
hypoxia. Representative flow cytometry analysis (relative UPN indicated) of AnnV/PI 
expression on TP53wt and TP53dis CLL cells exposed to 1 µM BAY87-2243 (BAY) or left 
untreated for 48 hours, under hypoxic conditions. BAY87-2243 exerted a cytotoxic effect 
also when TP53dis and TP53wt CLL cells were cultured in conditions of hypoxia. 
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Supplemental Figure 7 
 
Figure S7. Viability of TP53wt and TP53dis CLL cells exposed to BAY87-2243 in 
presence of SC. Representative flow cytometry analysis (relative UPN indicated) of 
AnnV/PI expression on TP53wt and TP53dis CLL cells exposed to 1 µM BAY87-2243 (BAY) 
or left untreated for 48 hours, in the presence or in the absence of the murine SC line M2-
10B4. BAY87-2243 exerted a cytotoxic effect also when TP53dis and TP53wt CLL cells 
were co-cultured with SC. 
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Supplemental Figure 8 
 
Figure S8. Viability of TP53wt and TP53dis CLL cells exposed to BAY87-2243 + 
fludarabine. Representative flow cytometry analysis (relative UPN indicated) of AnnV/PI 
expression on TP53dis and TP53wt CLL cells exposed for 48 hours to 1 μM BAY87-2243 
(BAY) and/or 10 μM F-ara-A. The combination BAY87-2243 + F-ara-A determined a 
significant decrease in the viability of TP53wt and TP53dis CLL cells, compared to each 
compound used as single agent and to untreated controls. 
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Supplemental Figure 9 
 
 
Figure S9. CI of BAY87-2243 + fludarabine combinations. Figure showing combination 
indexes (CI) relative to 48-hour treatment with BAY87-2243 (BAY) and F-ara-A, used at 
different concentrations in TP53wt and TP53dis CLL cells. CI<1, highlighted in bold, indicate 
synergistic combinations.  
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Supplemental Figure 10 
 
 
Figure S10. BAY87-2243 + fludarabine combination exerts a significant cytotoxic 
effect on TP53dis and TP53wt CLL cultured under hypoxia or in the presence of SC. 
Normalized cell viability of TP53dis and TP53wt CLL cells exposed for 48 hours to 1 μM 
BAY87-2243 (BAY) and/or 10 μM F-ara-A, under normoxia and hypoxia, or in co-culture 
with SC. The combination BAY87-2243 + F-ara-A (striped pattern) determined a significant 
decrease in the viability of TP53wt and TP53dis CLL cells, compared to each compound 
used as single agent, in condition of hypoxia (A, B) or in the presence of SC (C, D). In 
panels A and C, box plots represent median values and 25%-75% percentiles, whiskers 
represent minimum and maximum values for each group, together with all the points. In 
panels B and D, representative flow cytometry analysis (relative UPN indicated) of 
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AnnV/PI expression on TP53dis and TP53wt CLL cells exposed for 48 hours to 1 μM 
BAY87-2243 and/or 10 μM F-ara-A in the presence of SC. 
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Supplemental Figure 11 
 
Figure S11. Viability of TP53wt and TP53dis CLL cells exposed to BAY87-2243 + 
ibrutinib. Representative flow cytometry analysis (relative UPN indicated) of AnnV/PI 
expression on TP53dis and TP53wt CLL cells exposed for 48 hours to 1 μM BAY87-2243 
(BAY) and/or 10 μM ibrutinib. The combination BAY87-3342 + ibrutinib determined a 
significant decrease in the viability of TP53wt and TP53dis CLL cells, compared to each 
compound used as single agent and to untreated controls. 
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Supplemental Figure 12 
 
Figure S12. CI of BAY87-2243 + ibrutinib combinations. Figure showing combination 
indexes (CI) relative to the 48-hour treatment with BAY87-2243 (BAY) and ibrutinib, used 
at different concentrations in TP53wt and TP53dis CLL cells. CI<1, highlighted in bold, 
indicate synergistic combinations.  
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